Mammakarzinom der Frau

  • K. Possinger
  • H.-J. Schmoll
  • K. Höffken

Zusammenfassung

Häufigkeit: ca. 40000 Neuerkrankungen pro Jahr in der BRD, für Frauen zwischen dem 35. und 45. Lebensjahr ist das Mammakarzinom die häufigste Todesursache überhaupt. In Nordamerika und Nord- und Mitteleuropa treten Mammakarzinome etwa 5mal häufiger auf als in Asien und Südamerika.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  1. Antman KH (1992) Dose-intensive therapy in breast cancer. In: Armitage J, Antman K (eds) High-dose cancer therapy, pharmacology, hematopoietins, stem cells. Williams and Wilkins, Baltimore, vol 42, pp 701–713Google Scholar
  2. Armand JP et al. (1984) Phase III chemotherapy comparing FAC vs FEC in advanced breast cancer. Preliminary results. Proc ASCO 3:118, C-460Google Scholar
  3. Ashford RFU et al. (1984) Conservative excision and radiotherapy for early breast cancer–an acceptable alternative? Clin Oncol 10: 45–58PubMedGoogle Scholar
  4. Attia Sobol Jet al. (1993) Treatment results, survival and prognostic factors in 109 inflammatory breast cancers: univariate and multivariate analysis. Eur J Cancer 29A (8): 1081–1088CrossRefGoogle Scholar
  5. Australian and New Zealand Cancer Trials Group, Clinical Oncological Society of Australia (1986) A randomized trial in postmenopausal patients with advanced breast cancer comparing endocrine and cytotoxic therapy given sequentially as in combination. J Clin Oncol 4: 186–195Google Scholar
  6. Barai E et al. (1985) The effect of adjuvant radiotherapy on the time of occurence and prognosis of local recurrence in primary operable breast cancer. Cancer 56: 2779–2782CrossRefGoogle Scholar
  7. Bennett JM et al. (1985) A randomized multicenter trial of cyclophosphamide novantrone and fluorouracil (CNF) versus cyclophosphamide, adriamycin, 5-fluorouracil (CAF) in patients with metastatic breast cancer. Proc ASCO 4:26, C-493Google Scholar
  8. Blumenschein GR (1984) The role of progestins in the treatment of cancer. Semin Oncol [Suppl] 10: 7–10Google Scholar
  9. Bonadonna G (1989) Conceptual and practical advances in the managements of breast cancer. Karnosfsky Memorial Lecture. J Clin Oncol 7: 1380–1397PubMedGoogle Scholar
  10. Bonadonna G (1992) Evolving concepts in the systemic adjuvant treatment of breast cancer. Cancer Res 52 (8): 2127–2137PubMedGoogle Scholar
  11. Bonadonna G (1995) Future developments in adjuvant systemic therapy of breast cancer. 5th International Conference on Adjuvant Therapy of Primary Breast Cancer, St. Gallen, March 1–4, abs. 23Google Scholar
  12. Bonadonna G, Valagussa P (1985) Adjuvant systemic therapy of resectable breast cancer. J Clin Oncol 3: 259–275PubMedGoogle Scholar
  13. Bonadonna G et al. (1986) Adjuvant CMF in node negative breast cancer (abstract 290). Proc ASCO 5: 74Google Scholar
  14. Bonadonna G et al. (1990) Primary chemotherapy to avoid mastectomy in tumors with diameters of three centimeters or more. J Natl Cancer Inst 82: 1539–1544PubMedCrossRefGoogle Scholar
  15. Bonadonna G et al. (1991) Adjuvant and neoadjuvant treatment of breast cancer with chemotherapy and/or endocrine therapy. Semin Oncol 18: 515–524PubMedGoogle Scholar
  16. Breast Cancer Trials Committee (1987) Adjuvant tamoxifen in the management of operable breast cancer. The Scottish trial. Lancet 2: 171–175Google Scholar
  17. Brunner KW (1983) Stand der Chemotherapie beim metastasierenden Mammakarzinom. In: Kubli F, Nagel G, Kadach U, Kaufmann M (Hrsg) Neue Wege in der Brustkrebserkrankung, (Aktuelle Onkologie Bd 8 ), S 197–216. Zuckschwerdt, MünchenGoogle Scholar
  18. Buzdar AU et al. (1984) Breast cancer adjuvant therapy trials of M.D. Anderson Hospital: Results of two studies. In: Jones SE, Salmon SE (eds) Adjuvant therapy of cancer IV. Grune and Stratton, Orlando FLA, pp 217–225Google Scholar
  19. Canellos GP et al. (1974) Cyclical combination chemotherapy for advanced breast carcinoma. BMJ I: 218–220Google Scholar
  20. Carter C et al. (1989) Relation of tumor size, lymph-node status, and survival in 24,740 breast cancer cases. Cancer 63: 181PubMedCrossRefGoogle Scholar
  21. Castiglione M (1995) Adjuvant systemic therapy: the issue of timing and sequence. 5th International Conference on Adjuvant Therapy of Primary Breast Cancer, St. Gallen, March 1–4, abs. 21Google Scholar
  22. Cavalli F et al. (1983) Concurrent or sequential use of cytotoxic chemotherapy and hormone treatment in advanced breast cancer: Report of the Swiss Group for Clinical Cancer Research. BMJ 286: 5ffPubMedCrossRefGoogle Scholar
  23. Cobleigh MA et al. (1981) Phase II study of vindesine in patients with metastatic breast cancer. Cancer Treat Rep 65: 659–663PubMedGoogle Scholar
  24. De Jager R et al. (1982) Phase-II clinical trial of mitoxantrone in solid tumours and lymphomas. Proc ASCO 1: 89Google Scholar
  25. De Lena M et al. (1978) Combined chemotherapy and radiotherapy approach in locally advanced breast cancer. Cancer 1: 53–59Google Scholar
  26. Early Breast Cancer Trialists Collaborative Group (1992) Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy. 133 randomies trials involving 31000 recurrences and 24000 deaths among 75000 women. Lancet 339:1–5, 71–85Google Scholar
  27. Ehninger G et al. (1984) Mitoxantrone and cyclophosphamide in patients with advanced breast cancer. Cancer Treat Rep 68: 1283–1284PubMedGoogle Scholar
  28. Ehrlichman C et al. (1984) Male breast cancer: A 13 year review of 89 patients. J Clin Oncol 2: 903–909Google Scholar
  29. Fisher B et al. (1985a) Five-year results of a randomized clinical trial comparing total mastectomy and segmental mastectomy with or without radiation in the treatment of breast cancer. N Engl J Med 312:665–673CrossRefGoogle Scholar
  30. Fisher B et al. (1985b) Ten-year results of a randomized clinical trial comparing radical mastectomy and total mastectomy with or without radiation. N Engl J Med 312:674–681CrossRefGoogle Scholar
  31. Fisher B et al. (1986a) Adjuvant chemotherapy with and without tamoxifen in the treatment of primary breast cancer: 5-years results from the National Surgical Adjuvant Breast and Bowel Project trial. J Clin Oncol 4: 459–471PubMedGoogle Scholar
  32. Fisher B et al. (1986b) Ten years results from the National Surgical Adjuvant Breast and Bowel Project (NSABP) clinical trial evaluating the use of Lphenylalanine nustard (L-PAM) in the management of primary breast cancer. J Clin Oncol 4: 929–941PubMedGoogle Scholar
  33. Fisher B et al. (1987) Prolonging tamoxifen therapy for primary breast cancer. Findings from the National Surgical Adjuvant Breast and Bowel Project clinical trial. Ann Intern Med 106: 694–754CrossRefGoogle Scholar
  34. Gallagher CJ, Carinduff F, Smith IE (1987) High dose versus low dose medroxyprogesterone acetate: a randomized trial in advanced breast cancer. Eur J Cancer 23 (12): 1895–1900CrossRefGoogle Scholar
  35. Garcia-Conde J, Lluch A, Martin M et al. (1994) Phase II trial of weekly iv vinorelbine in first-line advanced breast cancer chemotherapy. Ann Oncol 5 (9): 854–857PubMedGoogle Scholar
  36. Goldhirsch A (Ludwig Breast Cancer Study Group) (1985) Randomized trial of chemo-endocrine therapy, and mastectomy alone in postmenopausal patients with operable breast cancer and axillary node metastasis. Lancet 1: 1256–1260Google Scholar
  37. Gutterman JU et al. (1976) Chemoimmunotherapy of advanced breast cancer: Prolongation of remission and survival with BCG. BMJ 11: 1222–1225CrossRefGoogle Scholar
  38. Harris JR et al. (1985) Limited surgery and radiotherapy for early breast cancer. N Engl J Med 313: 1365–1368PubMedCrossRefGoogle Scholar
  39. Heidemann E, Steinke B, Hartlapp J et al. (1990) Randomized clinical trial comparing Mitoxantrone with epirubicin and doxorubicin each combined with cyclophosphamide in the first line treatment of patients with metastasized breast cancer. Onkology 13: 24–27CrossRefGoogle Scholar
  40. Henderson JC (1984) Chemotherapy for advanced breast cancer. In: Bonadonna G (ed) Breast cancer: Diagnosis and management. Wiley, Chichester, pp 247–280Google Scholar
  41. Henderson JC (1985) Adjuvant chemotherapy of breast cancer: A promising experience or standard practice? J Clin Oncol 3: 140–143PubMedGoogle Scholar
  42. Hochster HS (1995) Combined doxorubicin/vinorelbine (Navelbine) therapy in the treatment of advanced breast cancerGoogle Scholar
  43. Höffken K, Jonat W, Possinger K et al. (1990) Aromatase inhibition with 4-Hydroxyandrostendione in the treatment of postmenopausal patients with advanced breast cancer: a phase II study. J Clin Oncol 8: 875–880PubMedGoogle Scholar
  44. Holmes FA (1994) Combination chemotherapy with taxol (paclitaxel) in metastatic breast cancer. Ann Oncol 5 [Suppl 6]: S23 - S27PubMedGoogle Scholar
  45. Ingle JN et al. (1986) Randomized trial of bilateral ophorectomy versus tamoxifen in premenopausal women with metastatic breast cancer. J Clin Oncol 4: 178–185PubMedGoogle Scholar
  46. Jacquillat C et al. (1990) Results of neoadjuvant chemotherapy and radiation therapy in the breast conserving treatment of 250 patients with all stages of infiltrative breast cancer. Cancer 66: 119–129PubMedCrossRefGoogle Scholar
  47. Jordan VC (1976) Effect of tamoxifen (ICI 46.474) on initiation and growth of DMBA-induced rat mammary carcinoma. Eur J Cancer 12: 419–424PubMedGoogle Scholar
  48. Jordan VC (1995) Tamoxifen and endometrial cancer: from experiment to patient. 5th Internatinal Conference on Adjuvant Therapy of Primary Breast Cancer, St. GallenGoogle Scholar
  49. Kufmann M, Jonat W, Kleeberg U for the German Zoladex Trial Group (1989) Goserelin, a depot gonadotropin-releasing hormone agonist in the treatment of premenopausal patients with metastatic breast cancer. J Clin Oncol 7, 1113–1119Google Scholar
  50. Lenaz L (1985) Mitomycin C in advanced breast cancer. Cancer Treat Rep 12: 235–249CrossRefGoogle Scholar
  51. Love RR et al. (1988) Bone mineral density in women with breast cancer treated with adjuvant tamoxifen for at least two years. Breast Cancer Res Treat 12: 297–301PubMedCrossRefGoogle Scholar
  52. Love RR et al. (1990) Effects of tamoxifen therapy on lipid and lipoprotein levels in postmenopausal patients with node-negative breast cancer. J Natl Cancer Inst 82: 1232–1237Google Scholar
  53. Margreiter R, Wiegele J (1984) Tamoxifen ( Nolvadex) for premenopausal patients with advanced breast cancer. Breast Cancer Res Treat 4: 45–48PubMedCrossRefGoogle Scholar
  54. Mattson W et al. (1982) A weekly schedule of low dose doxorubicin in the treatment of advanced breast cancer. Clin Ther 5: 193–203Google Scholar
  55. Michnocicz JJ, Bradlow HL (1990) Induction of estradiol metabolism by dietary indole-3-carbinol in humans. J Natl Cancer Inst 82 (11): 947–949CrossRefGoogle Scholar
  56. Moleterni A et al. (1991) Cyclophosphamide, methotrexate, and fluorouracil with and wihtout doxorubicin in the adjuvant treatment of resectable breast cancer with one to three positive axillary nodes. J Clin Oncol 9: 1124–1130Google Scholar
  57. Mouridsen HT (1986) Prednimustine in advanced breast cancer: a review. Semin Oncol 13 [Suppl 1]: 27–31PubMedGoogle Scholar
  58. Nayfield SG et al. (1991) Potential role of tamoxifen in prevention of breast cancer. J Natl Cancer Inst 83 (20): 1450–1459PubMedCrossRefGoogle Scholar
  59. Neidhardt JA et al. (1986) A comparison of mitoxantrone and doxorubicine in breast cancer. J Clin Oncol 4: 672–677Google Scholar
  60. Nemoto T et al. (1980) Management and survival of female breast cancer: Results of a national survey by the American College of Surgeons. Cancer 45: 2917PubMedCrossRefGoogle Scholar
  61. Osborne MP et al. (1984) Breast conservation in the treatment of early breast cancer. A 20-year follow up. Cancer 53: 349–355PubMedCrossRefGoogle Scholar
  62. Palangie T et al. (1994) Prognostic factors in inflammatory breast cancer and therapeutic implications. Eur J Cancer 30A (7): 921–927CrossRefGoogle Scholar
  63. Pasterz RB et al. (1985) Mitomycin in metastatic breast cancer refractory to hormonal and combination chemotherapy. Cancer 56: 2381–2384PubMedCrossRefGoogle Scholar
  64. Patel JK et al. (1986) Does more intense palliative treatment improve overall survial in metastatic breast cancer patients? Cancer 57: 567–570PubMedCrossRefGoogle Scholar
  65. Perez CA et al. (1994) Management of locally advanced carcinoma of the breast. 2. Inflammatory. Cancer 1: 74 [1 Suppl]: 453–465Google Scholar
  66. Peters WP (1995) High dose chemotherapy as adjuvant therapy for breast cancer: were do we stand? 5th International Conference on Adjuvant Therapy of Primary Breast Cancer, St. Gallen, March 1–4, abs. 19Google Scholar
  67. Planting AST et al. (1985) Tamoxifen therapy in premenopausal women with metastatic breast cancer. Cancer Treat Rep 69: 363–368PubMedGoogle Scholar
  68. Possinger K, Classen S, Beykirch M, Wilmanns W (1992) Idarubicin–oral wirksames Anthracyclin zur Behandlung metastasierter Mammakarzinome. Arzneimitteltherapie 5: 133–135Google Scholar
  69. Possinger K, Classen S, Beykirch M, Flath B, Wilmanns W (1991) Hormontherapie beim metastasierten Mammakarzinom der Frau. Dtsch Med Wochenschr 116, 1921–1929PubMedCrossRefGoogle Scholar
  70. Possinger K, Wilmanns W (1993) Palliative Therapieführung zur Hemmung der Tumorprogression bei Patientinnen mit metastasierten Mammakarzinomen. Internist 34: 340–350PubMedGoogle Scholar
  71. Possinger K, Carmichael J, Phillip P, Beykirch M, Kerr H, Walling J, Harris AL (1994) Advanced breast cancer: Experience with gemcitabine. In: Aapro MS (ed) Innovativa antimetabolites in solid tumours. Springer, Berlin Heidelberg New York Tokyo, pp 33–35CrossRefGoogle Scholar
  72. Powles TJ (1984) The role of aromatase inhibitors in breast cancer. Semin Oncol 10: 20–24Google Scholar
  73. Powles TJ et al. (1989) Chemoprevention of breast cancer. Breast Cancer Res Treat 14 (1): 22–31CrossRefGoogle Scholar
  74. Powles TJ et al. (1990) Prevention of breast cancer with tamoxifen: update of the Royal Marsden Hospital pilot programm. Eur J Cancer 26: 680–684PubMedCrossRefGoogle Scholar
  75. Ribeiro G et al. (1983) Adjuvant tamoxifen for operable carcinoma of the breast: report of clinical trial from the Christie Hospital and Holt Radium Institute. BMJ 286: 827PubMedCrossRefGoogle Scholar
  76. Rossi et al. (1981) Multimodal therapy in the operable breast cancer: Five-years results of the CMF-programme. BMJ 282: 1427–1431PubMedCrossRefGoogle Scholar
  77. Savka CA et al. (1986) Role and mechanism of action of tamoxifen in premenopausal women with metastatic breast carcinoma. Cancer Res 46: 3152–3156Google Scholar
  78. Schmid L, Possinger K (1993) Sind Bisphosphonate zur Therapie und Prophylaxe von Knochenmetastasen geeignet? Aktuell Onkol 73: 155–173Google Scholar
  79. Scholl SM et al. (1994) Neoadjuvant versus adjuvant chemotherapy in premenopausal patients with tumours considered too large breast conserving surgery: prelominary results of a randomised trial: S6. Eur J Cancer 30A (5): 645–652CrossRefGoogle Scholar
  80. Senn HF et al. (1978) Adjuvant chemoimmunotherapy with LMF + BCG in node-negative and node-positive breast cancer patients. Application cancer chemotherapy. Antibiot Chemother 24: 213–228PubMedGoogle Scholar
  81. Senn HJ (ed) (1984) Adjuvant chemotherapy of breast cancer. Recent Results in Cancer Research, vol 96. Springer, Berlin Heidelberg New York TokyoGoogle Scholar
  82. Sielmann M (1994) Taxol (paclitaxel) in patients with metastatic breast carcinoma who have failed prior chemotherapy: interium results of a multinational study. Oncology 51 [Suppl 11: 25–28CrossRefGoogle Scholar
  83. Singletary SE, McNeese MD, Hortobagyi GN (1992) Feasibility of breast-conservation surgery after induction chemotherapy for locally advanced breast carcinoma. Cancer 69 (11): 2849–2852PubMedCrossRefGoogle Scholar
  84. Smalley RV, Murphy S, Hugnley CM, Bartolucci AA (1976) Combination versus sequential five drug chemotherapy in metastatic carcinoma of the breast. Cancer Res 36: 3911–3914PubMedGoogle Scholar
  85. Smith EI et al. (1978) Vindesine: A phase II study in the treatment of breast carcinoma, malignant melanoma and other tumors. Cancer Treat Rep 62: 1427–1433PubMedGoogle Scholar
  86. Swenerton KD et al. (1979) Prognostic factors in metastatic breast cancer treated with combination chemotherapy. Cancer Res 39: 1552ffPubMedGoogle Scholar
  87. Tormey DC et al. (1982) A comparison of induction chemotherapies for metastatic breast cancer. Cancer 50: 1235–1244PubMedCrossRefGoogle Scholar
  88. Veronesi U et al. (1986) Local control and survival in early breast cancer: the Milan trial. Int J Radiat Oncol Biol Phys 12: 717–720PubMedCrossRefGoogle Scholar
  89. Wagstaff J et al. (1985) Rotating oral cyclophosphamide, methotrexate and fluorouracil (oral CMF) for patients with advanced carcinoma of the breast. Proc 3rd European Conference on Clinical Oncology, Stockholm. June 16–20 (Abs. 639 )Google Scholar
  90. Wander HE et al. (1985) Megestrolazetat in verschiedenen Dosierungen bei der Behandlung des metastasierenden Mammakarzinoms–Klinische and endokrinologische Untersuchungen.Klin Wochenschr 63: 312–318Google Scholar
  91. Yap H et al. (1981) Vindesine in the treatment of refractory breast cancer: Inprovement in therapeutic index with continuous 5-day infusion. Cancer Treat Rep 65: 775–779PubMedGoogle Scholar
  92. Yau JC et al. (1985) A comparative randomized trial of vinca alkaloids in patients with metastatic breast cancer. Cancer 55: 337–340PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1997

Authors and Affiliations

  • K. Possinger
  • H.-J. Schmoll
  • K. Höffken

There are no affiliations available

Personalised recommendations